X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (805) 805
Publication (149) 149
Book Review (7) 7
Book Chapter (6) 6
Conference Proceeding (1) 1
Data Set (1) 1
Dissertation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (521) 521
index medicus (484) 484
polo-like kinase-1 (418) 418
cell biology (331) 331
cell cycle proteins - metabolism (321) 321
protein-serine-threonine kinases - metabolism (315) 315
proto-oncogene proteins - metabolism (284) 284
animals (280) 280
phosphorylation (273) 273
mitosis (268) 268
cell cycle (239) 239
cancer (219) 219
plk1 (218) 218
biochemistry & molecular biology (204) 204
oncology (194) 194
polo-like-kinase-1 (178) 178
polo-like kinase 1 (172) 172
protein-serine-threonine kinases - antagonists & inhibitors (167) 167
polo-like kinase (166) 166
cell cycle proteins - genetics (162) 162
hela cells (159) 159
cell cycle proteins - antagonists & inhibitors (158) 158
proto-oncogene proteins - antagonists & inhibitors (158) 158
apoptosis (154) 154
protein-serine-threonine kinases - genetics (149) 149
cell line, tumor (143) 143
proteins (140) 140
kinases (138) 138
proto-oncogene proteins - genetics (137) 137
mice (125) 125
dna damage (108) 108
female (106) 106
research (103) 103
expression (93) 93
article (89) 89
cell division (88) 88
cytokinesis (86) 86
biology (85) 85
protein binding (78) 78
small-molecule inhibitor (77) 77
activation (74) 74
signal transduction (74) 74
protein kinase inhibitors - pharmacology (72) 72
cancer-cells (69) 69
male (67) 67
multidisciplinary sciences (67) 67
cell proliferation (65) 65
cell-cycle (64) 64
gene expression (64) 64
protein (64) 64
cells (63) 63
checkpoint (63) 63
protein-kinase (63) 63
box domain (62) 62
tumors (62) 62
research article (61) 61
rna interference (61) 61
binding (59) 59
dna (58) 58
genetics & heredity (58) 58
genetic aspects (57) 57
dna-damage (56) 56
analysis (54) 54
antineoplastic agents - pharmacology (54) 54
localization (54) 54
cell line (53) 53
spindle apparatus - metabolism (53) 53
deoxyribonucleic acid--dna (52) 52
mammalian-cells (52) 52
phosphotransferases (52) 52
aurora-a (50) 50
science (50) 50
protein kinases - metabolism (49) 49
apoptosis - drug effects (47) 47
cell proliferation - drug effects (47) 47
inhibition (47) 47
medicine (47) 47
physiological aspects (47) 47
chromosomes (46) 46
polo-like kinases (46) 46
pteridines - pharmacology (46) 46
aurora kinases (45) 45
biological phenomena, cell phenomena, and immunity (45) 45
in-vivo (45) 45
polo (45) 45
models, biological (44) 44
pharmacology & pharmacy (44) 44
down-regulation (43) 43
prognostic-significance (43) 43
blotting, western (42) 42
cell cycle - physiology (42) 42
cell-division (42) 42
mitosis - drug effects (42) 42
mitosis - physiology (42) 42
care and treatment (41) 41
centrosome - metabolism (41) 41
cycle (41) 41
inhibitor (41) 41
mutation (41) 41
cancer-therapy (40) 40
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


BMB Reports, ISSN 1976-6696, 2014, Volume 47, Issue 5, pp. 249 - 255
Journal Article
Lung Cancer, ISSN 0169-5002, 2016, Volume 104, pp. 126 - 130
Highlights • BI 2536 inhibits polo-like kinase 1 (Plk-1), a critical regulator of the cell cycle. • Plk inhibitors prevent growth of several small cell lung... 
Hematology, Oncology and Palliative Medicine | Pulmonary/Respiratory | BI 2536 | Polo-like kinase | Small cell lung cancer | Plk-1 inhibition | APOPTOSIS | NETWORK | ADVANCED SOLID TUMORS | POLO-LIKE-KINASE-1 | PLK1 | TRIAL | THERAPY | ONCOLOGY | RESPIRATORY SYSTEM | VOLASERTIB | TOPOTECAN | CARCINOMA | Lung Neoplasms - drug therapy | Recurrence | Humans | Middle Aged | Pteridines - adverse effects | Lung Neoplasms - pathology | Male | Pteridines - administration & dosage | Small Cell Lung Carcinoma - drug therapy | Cell Cycle Proteins - antagonists & inhibitors | Proto-Oncogene Proteins - adverse effects | Treatment Failure | Protein-Serine-Threonine Kinases - antagonists & inhibitors | Proto-Oncogene Proteins - therapeutic use | Adult | Female | Cell Cycle Proteins - therapeutic use | Proto-Oncogene Proteins - antagonists & inhibitors | Pteridines - pharmacology | Cell Cycle Proteins - adverse effects | Neoplasm Recurrence, Local | Treatment Outcome | Protein-Serine-Threonine Kinases - therapeutic use | Disease-Free Survival | Administration, Intravenous | Small Cell Lung Carcinoma - pathology | Protein-Serine-Threonine Kinases - adverse effects | Smoking - epidemiology | Aged | Neoplasm Staging | Lung cancer, Small cell | Care and treatment | Relapse | Polo | Diseases | Medical research | Medicine, Experimental
Journal Article
Journal Article
Tetrahedron, ISSN 0040-4020, 09/2018, Volume 74, Issue 39, pp. 5779 - 5790
A practical chromatography-free synthesis of a potent polo-like kinase-1 inhibitor possessing a unique 5,6-dihydroimidazolo[1,5- ]pteridine structure has been... 
Polo-like kinase-1 inhibitor | Amination | Chromatography-free synthesis | trans 1,4-cyclohexyldiamine | 5,6-dihydroimidazolo[1,5-f]pteridine | Piperazine ring formation | DESIGN | CHEMISTRY, ORGANIC | DRUG TARGETS | CANCER | ETHERS | LIGANDS | ARYL HALIDES | Stereoisomers | Pyrimidines | Aniline | Polo | Piperazine | Cyclohexane | Palladium | Chromatography
Journal Article
Cell Cycle, ISSN 1538-4101, 07/2014, Volume 13, Issue 14, pp. 2237 - 2247
Polo-like kinases (PLKs) and Aurora kinases (AKs) act as key cell cycle regulators in healthy human cells. In cancer, these protein kinases are often... 
Aurora kinases | MEK/ERK/mTORC1 | cell cycle | PI3K/Akt/mTORC2 | apoptosis | polo-like kinases | T-ALL | caspases | Polo-like kinases | Cell cycle | Caspases | Apoptosis | MAMMALIAN TARGET | RAPAMYCIN | ACUTE MYELOID-LEUKEMIA | ONCOGENIC TRANSFORMATION | CYTOTOXIC ACTIVITY | CANCER | CELL BIOLOGY | 1 PLK1 | PATHWAY | RESISTANCE | INHIBITOR BI 2536 | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma - pathology | Aurora Kinase B - metabolism | Apoptosis - drug effects | Coculture Techniques | Humans | Aza Compounds - pharmacology | Aurora Kinase A - antagonists & inhibitors | Molecular Targeted Therapy | Aurora Kinase A - metabolism | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Cell Cycle Proteins - antagonists & inhibitors | Dose-Response Relationship, Drug | G2 Phase Cell Cycle Checkpoints - drug effects | Drug Design | Protein-Serine-Threonine Kinases - antagonists & inhibitors | Indoles - pharmacology | Antineoplastic Agents - pharmacology | Tumor Cells, Cultured | Aurora Kinase B - antagonists & inhibitors | Protein-Serine-Threonine Kinases - metabolism | Proto-Oncogene Proteins - metabolism | Cell Survival - drug effects | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Proto-Oncogene Proteins - antagonists & inhibitors | Jurkat Cells | Cell Cycle Proteins - metabolism | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma - enzymology | Drug Synergism | Animals | Signal Transduction - drug effects | Cyclohexanecarboxylic Acids - pharmacology | Cell Proliferation - drug effects | Mice | Protein Kinase Inhibitors - pharmacology | Thiazoles - pharmacology | Report | Akt | MEK | PI3K | mTORC2 | mTORC1 | ERK
Journal Article
Journal of Biomolecular Structure and Dynamics, ISSN 0739-1102, 09/2019, Volume 37, Issue 13, pp. 3410 - 3421
Polo box domain (PBD) from Polo-Like Kinase-1 (PLK-1) a cell cycle regulator is one of the important non-kinase targets implicated in various cancers. The... 
molecular dynamics simulations | pharmacophore-based virtual screening | molecular docking | Polo-like kinase-1 Polo-box domain | PLHSpT phosphopeptide | LOCALIZATION | ENERGY | BIOCHEMISTRY & MOLECULAR BIOLOGY | PLK1 | PARTICLE MESH EWALD | IDENTIFICATION | GROMACS | CENTRIOLE DUPLICATION | BIOPHYSICS | INDUCE MITOTIC ARREST | CHARMM | TOOL
Journal Article
CELLS, ISSN 2073-4409, 02/2018, Volume 7, Issue 2, p. 13
Journal Article
by Dang, SC and Wang, F and Qian, XB and Abdul, M and Naseer, QA and Jin, W and Hu, R and Gu, Q and Gu, M
ONCOTARGETS AND THERAPY, ISSN 1178-6930, 2019, Volume 12, pp. 795 - 803
Purpose: The expression of micro RNA-505 (miR-505) has been investigated in various cancers; however, its effect and mechanism in relation to gastric cancer... 
EPITHELIAL-MESENCHYMAL TRANSITION | SURVIVAL | gastric cancer | ONCOLOGY | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | polo-like kinase-1 | EMT | MicroRNA-505 | Proteins | Cell growth | Chemotherapy | Medical prognosis | MicroRNAs | Metastasis | Gene expression | Kinases | Prostate | Experiments | Stomach cancer | Apoptosis | polo like kinase-1
Journal Article
BMB Reports, ISSN 1976-6696, 2014, Volume 47, Issue 5, p. 249
Polo-like kinase-1 (Plk1) belongs to a family of serine-threoninekinases and plays a critical role in mitotic progression. Plk1involves in the initiation of... 
DNA damage checkpoint | Polo-like kinase-1 | Cell cycle | p53
Journal Article
Journal Article
Bioengineering, ISSN 2306-5354, 12/2018, Volume 5, Issue 4, p. 83
Glioblastoma Multiforme (GBM) is a common primary brain cancer with a poor prognosis and a median survival of less than 14 months. Current modes of treatment... 
Enhanced permeability and retention | Polymeric nanoparticles | Polo-like kinase inhibitor | Cytotoxicity | Oncology | U-87 MG | GSK461364A | Glioblastoma multiforme | Oncomedicine | Glioblastoma Multiforme | polymeric nanoparticles | enhanced permeability and retention | oncomedicine | polo-like kinase inhibitor | cytotoxicity | oncology
Journal Article